April 29, 2020 / 2:10 PM / a month ago

BRIEF-Karo Pharma Q1 EBIT Up At SEK 104.1 Million

April 29 (Reuters) - Karo Pharma AB:

* Q1 NET SALES AT SEK 793.6 MILLION VERSUS SEK 420.8 MILLION YEAR AGO

* Q1 EBIT AMOUNTED TO MSEK 104.1 (87.4) CORRESPONDING TO A 19% GROWTH

* Q1 ADJUSTED EBITDA* AMOUNTED TO MSEK 213.2 (153.0) CORRESPONDING TO A 39% GROWTH

* ORGANIC GROWTH OF 27% WAS POSITIVELY IMPACTED BY COVID-19 CRISIS DRIVING INCREASED SALES WITHIN PAIN, COUGH & COLD, DERMATOLOGY AND RX PHARMA CATEGORIES

* MAIN DRIVER BEHIND STRONG SALES GROWTH WAS BUILD-UP OF INVENTORIES ACROSS WHOLESALERS, PHARMACIES, AND PRIVATE HOMES

* EXPECTS THIS ONE-OFF EFFECT PARTIALLY WILL BE REVERSED IN REMAINING THREE QUARTERS OF YEAR, NOTABLY IN Q2 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below